838P - Expression and clinical importance of e-cadherin, dysadherin and chemokine ligand 2 (CCL2) in renal cell carcinoma (RCC)

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Renal Cell Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Umut Demirci
Authors U. Demirci1, M. Yaman2, S. Buyukberber3, O. Ekinci4, S. Ozkan5, U. Coskun3, M. Benekli6, A. Ozet3, Ü.E. Bagriacik2
  • 1Medical Oncology, Atatürk Education and Research Hospital, 0906800 - Ankara/TR
  • 2Immunology, Gazi University Faculty of Medicine, Ankara/TR
  • 3Medical Oncology, Gazi University Faculty of Medicine, Ankara/TR
  • 4Pathology, Gazi University Faculty of Medicine, Ankara/TR
  • 5Public Health, Gazi University Faculty of Medicine, Ankara/TR
  • 6Medical Oncology, Gazi University Faculty of Medicine, 090 - Ankara/TR



Dysadherin is a cell adhesion molecule that related with aggresiveness and progression in many cancers. Dysadherin acts role either with E-cadherine dependent or CCL-2 mediated that E-cadherin independent. We studied expression and clinical importance of dysadherin and e-cadherin as adhesion molecules and CCL2 in RCC.


Between 2006 and 2010, 38 patients with RCC were evaluated retrospectively. Median age of the patients (27 male, 11 female) was 60 (range, 33–84). While median tumor size was 5.75 cm (range, 2–30 cm), 13 patients were stage 4, one patient was stage 3, 5 patients were stage 2, 19 patients were stage 1. 15 patients were Fuhrmann grade ¾, 21 patients (55.3%) had capsule invasion, 10 patients (26.3%) had perirenal fat tissue involvement and 4 patients had (10.5%) renal vein thrombosis. Dysadherin did not express in 10 patients. Low expression (less than %30) was detected in 25 patients (65.8%), enhanced expression (more than 30%) was detected in 3 patients (%7.9). E-cadherin did not express in 11 patients (28.9%), low expression was detected in 23 patients (60.5%), moderate-high expression was detedcted 4 patients (10.6%). CCL2 did not express in 14 patients, low expression was detected in 7 patients (%18.4), moderate-high expression was detected in 17 patients (44.3%). Although moderate positive correlation between dysadherin and CCL2 (r= +0,25, p = 0.49), e-cadherin and CCL2 (r= +0.25, p = 0.33) were detected, moderate negative correlation between dysadherin and e-cadherin was detected (r= +0.22, p = 0.66). Moderate negative correlation was detected between grade of tumor and e-cadherin (r= -0.25, p = 0.49). Median overall survival (OS) was 46.6 months (range, 38.9-54.3), In univariate analysis, stage, grade of tumor, capsule invasion, tumor thrombosis, perirenal fat tissue involvement were significant interaction on OS (p < 0.05), however dysadherin, E-cadherin and CCL2 were not associated with OS (>0.05). Stage and vascular thrombosis were significant on overall survival in multivariate analysis.


This is the first study that evaluated adhesion molecules in RCC and there is no association these parameters and clinical outcome.


All authors have declared no conflicts of interest.